Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07465198 Autologous Stem Cell Therapy(Biocells Medical) Multiple System Atrophy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07465198 clinical trial report covering Autologous Stem Cell Therapy(Biocells Medical), Phase 2, endpoints, sponsor, geography, readout timing and devel
Latest Hotspot
8 min read
ChiCTR2600120353 FNS-007 Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120353 clinical trial report covering FNS-007, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600120362 Apalutamide HER2 negative Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ChiCTR2600120362 clinical trial report covering Apalutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07463820 Epoetin Alfa Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07463820 clinical trial report covering Epoetin Alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07466927 Trastuzumab Rezetecan HER2-negative breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07466927 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467993 GXV-813 Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07467993 clinical trial report covering GXV-813, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07467772 Elacestrant hydrochloride Adenosarcoma of the Uterus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07467772 clinical trial report covering Elacestrant hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07466303 Serplulimab Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07466303 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ACTRN12626000316303 Psilocybin Alcohol Use Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
ACTRN12626000316303 clinical trial report covering Psilocybin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07466017 Semaglutide (Novo Nordisk) Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07466017 clinical trial report covering Semaglutide (Novo Nordisk), Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07465757 Alisertib Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07465757 clinical trial report covering Alisertib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07469098 Methylenedioxymetamfetamine Stress Disorders, Post-Traumatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
27 August 2026
NCT07469098 clinical trial report covering Methylenedioxymetamfetamine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.